Clouded in the murkiness of the debate surrounding the use of the PSA test is an increasing escalation of younger men (under the age of 50 years) being diagnosed with advanced prostate cancer. We know that there has been escalating incidence rate (IR) of prostate cancer PC noted in the last two decades. Many have [...]
It is known that Zoledronic acid (ZA) reduces the risk of developing skeletal-related events (SRE) which are caused by bone metastasis in prostate cancer (PCa). ZA also improves the quality of life (QOL). ZA has become a standard supportive therapy for men with prostate cancer who have bone metastasis. The big unknown is when should [...]
Last April there was some preliminary data from the long-term Phase II STAND study presented at 29th Annual European Association of Urology (EAU) Congress that showed that sipuleucel-T (Provenge) when given after the start of androgen deprivation therapy (ADT) seemed to enhance and sustain the immune response in men with a biochemical failure (PSA only) [...]
The vast majority of men with advanced prostate cancer will eventually develop bone metastases. Given this fact it is important to understand what is meant by the term bone metastases. Bones serve as the supporting framework of our bodies. Like the rest of us bones are constructed of cells. These cells compose a network or [...]
The following was written and posted by Paul Edwards to the Advanced Prostate Cancer Online Support Group: The March 2014 issue of the Asia-Pacific Journal of Clinical Oncology published an article “Why do some cancer patients receiving chemotherapy choose to take complementary and alternative medicines and what are the risks?” by authors from University of Queensland [...]
Docetaxel is the only globally approved first-line chemotherapy for the treatment of castrate resistant prostate cancer. Yhe universal truth is that all men taking docetaxel will become refractory to the treatment. Zoledronic acid (ZA) is the most commonly used member of nitrogen-containing bisphosphonate family. By itself it has anti-tumor activity, including in prostate cancer. In [...]
Researchers have reported ahead of print that substance use disorders may adversely affect outcomes in men with advanced prostate cancer This conclusion was drawn from a very large study of 14,277 men with advanced prostate cancer. The study found that men with advanced prostate cancer along with a substance abuse disorder were 2.3 times more [...]
British Men Who Have Had Abiraterone Will Not Get Enzalutamide Despite Its Life Extending Ability Our brothers in England hit a major snag last week as NHS placed a burdensome restriction on the use of enzalutamide (Xtandi) for men with advanced prostate cancer who have already had abiraterone (Zytiga). Because of this ridiculous decision thousands [...]
There are conferences for doctors and conferences for researchers, but there is also a conference just for prostate cancer survivors and their caretakers! The Prostate Cancer Research Institute (PCRI), a partner of Malecare, annually sponsors the only patient conference in the world. I have attended the conference over the last five years and strongly recommend [...]
In my most humble opinion among the most vital and impactful program in the world, which supports prostate cancer research funding and prostate cancer research resources, is in trouble. It is the only government program that funds only prostate cancer research. All of its research funding mechanisms are designed to fund high risk and potentially [...]
